Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 156 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MmHuR5l1d3SxeHnjJGF{e2G7 NXXVNYs6PTBizszN MUG0PEBp M3zWfWROW09? M2TvWWtqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> MlfvNVA1QTl4NEO=
OVCA 429 M3vrZ2Z2dmO2aX;uJGF{e2G7 NWnsOWFSOzByIH7N NFLmfmE1QCCq NV;6cVhyTE2VTx?= MlfJSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz NUHPTotkOTB7OUm3OlY>
RPMI8226 NV;oT2w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzD[XcyODBibl2= MoHHOFghcA>? M1HWfmROW09? NYm3NZBoUUN3ME2zNEBvVQ>? MnjvNVE{ODZ2OEm=
Dox40 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7tRmkyODBibl2= Mnv1OFghcA>? NVH3[mV4TE2VTx?= MVjJR|UxRTRyIH7N M{T5ZVEyOzB4NEi5
MR20 NEjBVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xNFAhdk1? NH\HTpY1QCCq NYfm[WRLTE2VTx?= NG\INnhKSzVyPUKwJI5O M{X3WlEyOzB4NEi5
LR5 NIn5em5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLQUIl[OTByIH7N NWnrW|NEPDhiaB?= MUnEUXNQ MnzhTWM2OD1{MDDuUS=> M3TjWFEyOzB4NEi5
U266 NYHUdlRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTvPHBlOTByIH7N MlrhOFghcA>? M2rMVmROW09? NHHTeIpKSzVyPUOgcm0> NIG4eoIyOTNyNkS4PS=>
IM-9 M1uydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\MNVAxKG6P MnTHOFghcA>? MmPXSG1UVw>? MXPJR|UxRTZibl2= NID2ToMyOTNyNkS4PS=>
Hs Sultan M2nBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrjOnMyODBibl2= NXvkO3JjPDhiaB?= MY\EUXNQ MUjJR|UxRTJyIH7N M37r[|EyOzB4NEi5
PAM-LY2 NYXYTplHTnWwY4Tpc44hSXO|YYm= NEnmdoUyODBibl2= MmXkNVIhcA>? MUHEUXNQ MXvJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= NHz1[XkyOTN3MEmxNy=>
PAM 212 NVHoUItnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxNFAhdk1? M1jrO|czKGh? MWLEUXNQ NIXGN25KdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M4jmblEyOzVyOUGz
PAM-LY2 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT4NVAxKG6P Moj4O|IhcA>? MoTZSG1UVw>? NEDLTnRKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NVjSdG06OTF|NUC5NVM>
B4B8 M2iyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvhOnRlOTByIH7N MWK3NkBp MlvCSG1UVw>? NUnuVWhtUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M1PwPFEyOzVyOUGz
B7E3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fZXlExOCCwTR?= NFPuRXc4OiCq M3fGSGROW09? NFnMNplKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M1jjTlEyOzVyOUGz
UM-SCC-9 NYn2dmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LOeFExOCCwTR?= MVu3NkBp MWXEUXNQ M2HwdGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NHHwVVcyOTN3MEmxNy=>
UM-SCC-11B MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILjdVYyODBibl2= M{nnRVczKGh? M3nZcmROW09? MoraTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M1fG[FEyOzVyOUGz
H460 M33tTWZ2dmO2aX;uJGF{e2G7 MUSxNEDPxE1? NFj5RXAzPCCq NXvOUIltTE2VTx?= MnnpTY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>? M3jHPVEzPDl{MUG3
U266 NGXnZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPVZ2I2ODBibnevcYw> MUi0PEBp Ml;mSG1UVw>? NUnuXpc1UW6qaXLpeJMh[2WubDDndo94fGh? MWCxNlY{OTZzOR?=
ARH77 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTaOVAxKG6pL33s MoLGOFghcA>? MnrlSG1UVw>? MoqwTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MWSxNlY{OTZzOR?=
WAD-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P1RVUxOCCwZz;tcC=> MWq0PEBp M3HWTWROW09? M1L1emlvcGmkaYTzJINmdGxiZ4Lve5Rp MXexNlY{OTZzOR?=
U266/LR7 NU\SZYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn0RWt6PTByIH7nM41t MV20PEBp NFf2UYJFVVOR NYjrUll1UW6qaXLpeJMh[2WubDDndo94fGh? NH\xNmsyOjZ|MU[xPS=>
U266/dox4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDIOos2ODBibnevcYw> MmX3OFghcA>? MXnEUXNQ NY\6e|JTUW6qaXLpeJMh[2WubDDndo94fGh? NFHI[JQyOjZ|MU[xPS=>
RPMI8226/LR5 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf5fnNLPTByIH7nM41t Ml\FOFghcA>? NX;4SIh3TE2VTx?= M3X0cmlvcGmkaYTzJINmdGxiZ4Lve5Rp M3PCOVEzPjNzNkG5
H460 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHkW45iOTBizszN MYe3NkBp MYXEUXNQ M1LjV2lEPTB;MUCwJI5O NXPaUZZkOTJ4M{G2NlA>
H358 M1mwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXvNWoyOCEQvF2= Mmr0O|IhcA>? M1jIfmROW09? NWTLc29PUUN3ME23NEBvVQ>? MmPKNVI3OzF4MkC=
H322 NHfPWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDRNVAh|ryP MoewO|IhcA>? MWrEUXNQ NILrNWlKSzVyPU[yNEBvVQ>? NE\UUZoyOjZ|MU[yNC=>
H460 NEXvSYxHfW6ldHnvckBCe3OjeR?= M{Swe|ExOCCwTR?= MoTrNlQhcA>? MVvEUXNQ NGnVelZKdmS3Y3XzJGczNU1vcHjhd4Uh[XK{ZYP0JIFv\CC2dXL1cIlvKGG|c3XtZox6NWSrc3Hzd4Vu[my7 M1jCNlEzPjNzNkKw
LNCap-Pro5 NEDublNHfW6ldHnvckBCe3OjeR?= M1z3bFEh|ryP Mo\sOEBp MorUSG1UVw>? MVrTeIFjcWyrenXzJJA2Ow>? MUmxOFYyOjV|Mh?=
T29 NFG0OmFCeG:ydH;zbZMhSXO|YYm= NITXWGQ2OCCwTR?= NHjHZ2w1QCCqIB?= MUTEUXNQ MmXVTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVfjPHZUOTZ5N{ixO|k>
T29Kt1 MmjvRZBweHSxc3nzJGF{e2G7 MkmwOVAhdk1? NISxbYk1QCCqIB?= MluzSG1UVw>? MW\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MYGxOlc4QDF5OR?=
HCT116 NH\jcnFCeG:ydH;zbZMhSXO|YYm= NGPITm02OCCwTR?= NVnhRpA1PDhiaDC= M{faTmROW09? NYr0NIhpUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NULKb49kOTZ5N{ixO|k>
HKe-3 NU\lSYtSSXCxcITvd4l{KEG|c3H5 MV[1NEBvVQ>? M3fVPFQ5KGhi Mm\GSG1UVw>? MWrJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M{fXfVE3Pzd6MUe5
NB-1691 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rHVVEh|ryP Mkm2O|IhcA>? NELhV|FKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= MYSxO|Y5QTZ6NB?=
CHLA-255 NXfO[lBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLENUDPxE1? Mlm4O|IhcA>? NHv4UYRKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= MkD0NVc3QDl4OES=
SK-N-AS NHnle25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxJO69VQ>? MWG3NkBp NUPoRYk{UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> MUmxO|Y5QTZ6NB?=
NB-1691 M1;2WGZ2dmO2aX;uJGF{e2G7 MnuxNVAhdk1? NHW0PXYzPCCq Ml25V4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> NX3jUolIOTd4OEm2PFQ>
CHLA-255 NYHMNJFUTnWwY4Tpc44hSXO|YYm= NUPTWIgxOTBibl2= NXjONGd6OjRiaB?= NHrpTWlOd2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= MXWxO|Y5QTZ6NB?=
RPMI 8226 NY\lTnJnTnWwY4Tpc44hSXO|YYm= MX2yNEBvVQ>? NVu2WWFmQCCq NETj[4JUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NGfNTpEyQTR|NkC1NC=>
MM.1S NXLqUFNnTnWwY4Tpc44hSXO|YYm= MVuyNEBvVQ>? MkTSPEBp Mmn0V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M2PEPFE6PDN4MEWw
U266 NV60V3N{TnWwY4Tpc44hSXO|YYm= M2OwOVIxKG6P MmXKPEBp NVTLS2pDW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NVLZVHkzOTl2M{[wOVA>
OPM1 Moq2SpVv[3Srb36gRZN{[Xl? Mo\HNlAhdk1? MXS4JIg> NH3oU5RUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M4iwSlE6PDN4MEWw
INA6 M1vMZmZ2dmO2aX;uJGF{e2G7 NU\0ZW9mOjBibl2= NY\kVm9RQCCq MY\TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MUWxPVQ{PjB3MB?=
OPM2 NGqwR|FHfW6ldHnvckBCe3OjeR?= NFrUWHMzOCCwTR?= NVLHU2ZnQCCq MV7TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M2rlWlE6PDN4MEWw
RPMI 8226 MVrGeY5kfGmxbjDBd5NigQ>? NW[3enBiOjBibl2= MUi4JIg> MnTrTY5lfWOnczDEUmEhe3mwdHjld4l{ NULPUlV5OTl2M{[wOVA>
BaF/3 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNFAhdk1? M{XkeFQ5KGh? NGfiRoVKSzVyPU[uNkBvVQ>? MX:yNFMxPTZ7Mh?=
BaF/3-p210 M{DU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i5[lExOCCwTR?= NUXYZWVUPDhiaB?= M13Ue2lEPTB;ND63JI5O M4\UXFIxOzB3Nkmy
TCC-S MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDmdHd3OTByIH7N M2XjRVQ5KGh? NIP0NplKSzVyPUKuPEBvVQ>? MX6yNFMxPTZ7Mh?=
BaF/3 M3HDcWZ2dmO2aX;uJGF{e2G7 M1n0UVYhdk1? MX:0PEBp NXzOTmc1UW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MVOyNFMxPTZ7Mh?=
BaF/3-p210 MYrGeY5kfGmxbjDBd5NigQ>? NEnsPXQ3KG6P NWHtTHh6PDhiaB?= M4nEO2lv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MkLGNlA{ODV4OUK=
BaF/3-p210 MkjtSpVv[3Srb36gRZN{[Xl? MV:2JI5O M1[3blI1KGh? NI\yVJFT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?= NYjJUZdoOjB|MEW2PVI>
Raji M3\IV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOxJO69VQ>? NHPzOoYzPCCq NF3vOnVT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NW\tdFRROjFzN{C5PFg>
LCL-1 Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P3PFEh|ryP MV6yOEBp MofVVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MUGyNVE4ODl6OB?=
LCL-2 M4PHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTiT2hROSEQvF2= MViyOEBp MmnwVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MUiyNVE4ODl6OB?=
BJAB NWnBW|NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPqcWtFOSEQvF2= M2j2[lI1KGh? MlfOVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MWiyNVE4ODl6OB?=
SNT-13 NU\mfpQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr0fIV4OSEQvF2= Mkj6NlQhcA>? M1zGUHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M{fKNlIyOTdyOUi4
SNT-16 NGDPVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuV|Eh|ryP MVSyOEBp NFLOZo5T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NHjCemgzOTF5MEm4PC=>
Jurkat MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3MNUDPxE1? NFjxRlgzPCCq NUnKW4JVWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg Mo[1NlEyPzB7OEi=
KAI-3 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTSfVUyKM7:TR?= NHHFRlIzPCCq NX;TOJdqWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M4PISlIyOTdyOUi4
SNK-6 NV6yRoN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vwWFEh|ryP M1;1NVI1KGh? MVTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NHTPRWszOTF5MEm4PC=>
KHYG-1 NFKyTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm5bVUyKM7:TR?= M4S0elI1KGh? MlnCVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NV\xOllOOjFzN{C5PFg>
SNT-16 MYrBdI9xfG:|aYOgRZN{[Xl? M4jqdFEh|ryP MYm2JIg> MX3JcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUjsO5hTOjFzN{C5PFg>
Jurkat NWrUO|hiSXCxcITvd4l{KEG|c3H5 Mnv4NUDPxE1? NVjQd3BqPiCq NH7KelZKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{P2UFIyOTdyOUi4
KAI-3 MWXBdI9xfG:|aYOgRZN{[Xl? NYPLbWhROSEQvF2= M{\NUVYhcA>? MkHkTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVjYPGc3OjFzN{C5PFg>
KHYG-1 MX3BdI9xfG:|aYOgRZN{[Xl? NELVdVgyKM7:TR?= NEn2SII3KGh? MVjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXvycpd3OjFzN{C5PFg>
SNT-13 NWnRSHpISW62aY\pdoFtKEG|c3H5 NEnKdXIyKM7:TR?= NULUUZNwOjRiaB?= MnnCTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NG\5b20zOTF5MEm4PC=>
SNT-16 MoO1RY51cX[rcnHsJGF{e2G7 Mnv2NUDPxE1? NIPiUYozPCCq M13ab2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? M2HMb|IyOTdyOUi4
KAI-3 NYjOS29KSW62aY\pdoFtKEG|c3H5 NFXxUIoyKM7:TR?= Mn7sNlQhcA>? NIXLW49KdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NXvhdHpUOjFzN{C5PFg>
SNK-6 MXvBcpRqfmm{YXygRZN{[Xl? M3v1XFEh|ryP MXSyOEBp MVvJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M3\nNlIyOTdyOUi4
RAW 264.7 M1zXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\HOZkyODBibl2= MkjvOFghcA>? NEPUfo1T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NHjkS5MzOjR{N{G1OC=>
A375 MlniRZBweHSxc3nzJGF{e2G7 M4LBUVExKG6P Mnz2NlQhcA>? M1nsVWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2K5TVI{ODd7MEiz
BLM NF\w[ppCeG:ydH;zbZMhSXO|YYm= Mk[zNVAhdk1? M4m4S|I1KGh? NYm4VFc6UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYOyN|A4QTB6Mx?=
A375 NEDaUmNCfXSxcHjh[5khSXO|YYm= NVLsZY5lOTBibl2= NIjob5cyOiCq NFjNbmxKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MYqyN|A4QTB6Mx?=
BLM M4i2ZWF2fG:yaHHnfUBCe3OjeR?= NWLwXYFYOTBibl2= MYWxNkBp MXnJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MY[yN|A4QTB6Mx?=
H1299 NVvkN29PSXCxcITvd4l{KEG|c3H5 NHqyNmo5OCCwTR?= MXSyOEBp MX\EUXNQ M4jFcXNmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| MUSyOVMzOzZ7Mx?=
Hut-78 M4PFTWZ2dmO2aX;uJGF{e2G7 MXOxNFAhdk1? Mlv1NlQhcA>? MVnEUXNQ MXPEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25? NWrCO2dWOjV4OEGzN|U>
H9 MYHGeY5kfGmxbjDBd5NigQ>? M3XwSlExOCCwTR?= M{XUZVI1KGh? M17PNmROW09? M2TP[WRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= MXiyOVY5OTN|NR?=
HH NUDMdncyTnWwY4Tpc44hSXO|YYm= MW[xNFAhdk1? NXn2dVhQOjRiaB?= M1;j[WROW09? MYXkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? MlLRNlU3QDF|M{W=
Hut-78 M{SxUm1q\3KjdHnvckBCe3OjeR?= NWW1SlIzOTByIH7N M1PFcFI1KGh? MX3EUXNQ M{HnfXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= NFf5SHQzPTZ6MUOzOS=>
HH MVrNbYdz[XSrb36gRZN{[Xl? MWOxNFAhdk1? M4jkWVI1KGh? NFjTTVJFVVOR M3vIWnJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= MUiyOVY5OTN|NR?=
U937 M1znPGZ2dmO2aX;uJGF{e2G7 NUnobmtjOTByIH7N NGLXT243KGh? MoLtTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? MXWyOVc6OTR5Nx?=
human PBMC M2TCV2Z2dmO2aX;uJGF{e2G7 NXTMUVZsOTByIH7N Mnz6NlQhcA>? NWDzZmU6UW6mdXPld{BKVC16IILlcIVie2V? MmL1NlU4QTF2N{e=
ES6 NXL3TWNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMECyNUBvVQ>? NYTtfIdYW0GQR1XS
SK-UT-1 M{T0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4joTGlEPTB;MD6xOlMhdk1? M2r2ZnNCVkeHUh?=
SH-4 M1jVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vlVWlEPTB;MD6xO|Mhdk1? MWfTRW5ITVJ?
TE-9 M4fz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\q[WlEPTB;MD6xPFIhdk1? MWfTRW5ITVJ?
A253 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMkC4JI5O MV3TRW5ITVJ?
no-10 NI[weoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfWOGtRUUN3ME2wMlIyKG6P M3nCdnNCVkeHUh?=
MMAC-SF NGLadWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW0U5dKSzVyPUCuNlE3KG6P Mne4V2FPT0WU
A101D M2q4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\QepRKSzVyPUCuNlI2KG6P MmDlV2FPT0WU
NTERA-S-cl-D1 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqwRlNiUUN3ME2wMlI1OyCwTR?= NX\jRWFoW0GQR1XS
8-MG-BA NVnadpZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfPSmdKSzVyPUCuNlUhdk1? NEjLXHVUSU6JRWK=
KNS-42 M1m4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMkW4JI5O NX:4eIloW0GQR1XS
LXF-289 NXSzOVM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvselhKSzVyPUCuNlY6KG6P NFL3RmlUSU6JRWK=
OVCAR-4 M{DuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMki5JI5O M2PqW3NCVkeHUh?=
LOUCY MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULuTJp3UUN3ME2wMlI6OyCwTR?= M1rxXnNCVkeHUh?=
BB65-RCC NHfWO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr0So9KSzVyPUCuN|A1KG6P NVXiZ4U5W0GQR1XS
D-542MG NG\ZZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK5TWM2OD1yLkOyPUBvVQ>? NUWxeYVYW0GQR1XS
ONS-76 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK4TJhKSzVyPUCuN|Mhdk1? NX7GO2JuW0GQR1XS
BB30-HNC MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXycGxKSzVyPUCuN|M2KG6P MYPTRW5ITVJ?
KS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuzZ5RkUUN3ME2wMlM1KG6P MlTxV2FPT0WU
A388 M2q3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwM{W2JI5O M{KydnNCVkeHUh?=
ES8 NEDhU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT0cWVPUUN3ME2wMlQhdk1? MVHTRW5ITVJ?
MZ2-MEL Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfkTWM2OD1yLkSwO{BvVQ>? MVrTRW5ITVJ?
HCC2998 NH\Fe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3mXpl1UUN3ME2wMlQyOiCwTR?= NYPYRmJZW0GQR1XS
D-247MG NH7EXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNEGzJI5O MUnTRW5ITVJ?
ACN M{DsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DDNGlEPTB;MD60NVchdk1? MmrYV2FPT0WU
LB2518-MEL NEjTPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHlWJFpUUN3ME2wMlQzPSCwTR?= MUjTRW5ITVJ?
ES1 M{jqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj5TWM2OD1yLkSzJI5O M3jnV3NCVkeHUh?=
HCE-T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ZPWlEPTB;MD60N|khdk1? NVn2VI94W0GQR1XS
OS-RC-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwNESgcm0> NHT4bnZUSU6JRWK=
MFH-ino M4\Ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlToTWM2OD1yLkS0N{BvVQ>? M17ueXNCVkeHUh?=
OCUB-M MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33vemlEPTB;MD60OFchdk1? NWLJeVM1W0GQR1XS
CP66-MEL M320Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwNEezJI5O M{fJbHNCVkeHUh?=
LB771-HNC MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrNXplKSzVyPUCuOFc1KG6P MmnPV2FPT0WU
DSH1 M2j3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rhWmlEPTB;MD60PEBvVQ>? MnrzV2FPT0WU
HUTU-80 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PiOWlEPTB;MD61N|Mhdk1? MWPTRW5ITVJ?
CESS NFjvUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwNUO4JI5O NWrPOmpQW0GQR1XS
NCI-H747 NXXwc4FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTYVYdKSzVyPUCuOVM6KG6P M{\O[XNCVkeHUh?=
HT-144 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DhNmlEPTB;MD61O|Yhdk1? NV65TZNFW0GQR1XS
COLO-829 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n2e2lEPTB;MD62NVQhdk1? MoDrV2FPT0WU
A4-Fuk MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxTWM2OD1yLk[yN{BvVQ>? Mn7VV2FPT0WU
GI-ME-N M1jPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPlNFJZUUN3ME2wMlY{PCCwTR?= M1GzSnNCVkeHUh?=
LB831-BLC M2rXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwNkSxJI5O NYPxZWhvW0GQR1XS
HOP-62 M{T0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jNZ2lEPTB;MD62OFchdk1? MWPTRW5ITVJ?
BB49-HNC M1zFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXE[HNKSzVyPUCuOlUzKG6P NXfXT2dGW0GQR1XS
D-336MG M2HTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;4TmlEPTB;MD62OVchdk1? MVrTRW5ITVJ?
TK10 NXKwbGR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[4TWM2OD1yLk[3PUBvVQ>? NX\rd3E5W0GQR1XS
Ramos-2G6-4C10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTjTWM2OD1yLk[5N{BvVQ>? M3fGSHNCVkeHUh?=
LB373-MEL-D Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG0SINKSzVyPUCuO{BvVQ>? NGH1S4RUSU6JRWK=
SF126 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqzTWM2OD1yLkewNUBvVQ>? M4TpWHNCVkeHUh?=
UACC-257 NHXB[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jSPGlEPTB;MD63NUBvVQ>? M3nFUnNCVkeHUh?=
KINGS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPZeZpEUUN3ME2wMlczOiCwTR?= NWm0c4pjW0GQR1XS
LS-513 NY\DUocxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXp[YlWUUN3ME2wMlc{QSCwTR?= M3;SXnNCVkeHUh?=
GI-1 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTITWM2OD1yLke2OEBvVQ>? MWTTRW5ITVJ?
ES7 NIKwdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvNTmRtUUN3ME2wMlc3PiCwTR?= MVjTRW5ITVJ?
LB2241-RCC NWLDNmZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTkVGRIUUN3ME2wMlgxPCCwTR?= NHTVT41USU6JRWK=
D-263MG M2jseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljqTWM2OD1yLkiwO{BvVQ>? MmTaV2FPT0WU
SW684 NGLS[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrITWM2OD1yLkiyNUBvVQ>? NVzEcWFvW0GQR1XS
ML-2 Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwOEKxJI5O NX73Uph7W0GQR1XS
SK-LMS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHHSJh[UUN3ME2wMlg2PCCwTR?= NH\3XXBUSU6JRWK=
TE-5 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwOE[1JI5O NYnvVnBbW0GQR1XS
QIMR-WIL NVXmbnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwOEi5JI5O NHHyd4JUSU6JRWK=
NCI-H1355 M2H3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr5TWM2OD1yLki5OUBvVQ>? MkDKV2FPT0WU
SNB75 M2XrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwOUGyJI5O MmrNV2FPT0WU
RXF393 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzZdphKSzVyPUCuPVE1KG6P MnHwV2FPT0WU
IST-MEL1 NEnMZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6dodKSzVyPUCuPVE4KG6P M{PLPHNCVkeHUh?=
SF268 M2nJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjqTWM2OD1yLkmyN{BvVQ>? NUj2e5RxW0GQR1XS
KALS-1 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzLcYNKSzVyPUCuPVI2KG6P NXrnO2FtW0GQR1XS
HC-1 M3S2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS0NFMzUUN3ME2wMlk4PSCwTR?= Ml6yV2FPT0WU
SW872 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwOUm2JI5O MYTTRW5ITVJ?
PSN1 NUOycWtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzqXoxwUUN3ME2xMlAyKG6P MWTTRW5ITVJ?
TE-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7BPI5oUUN3ME2xMlA{KG6P MnLtV2FPT0WU
TE-10 NHj4dFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf0R2FMUUN3ME2xMlA{KG6P NYT6UpRFW0GQR1XS
RKO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrPOZRKSzVyPUGuNFYhdk1? MVLTRW5ITVJ?
LC-2-ad M3fNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVUmlEPTB;MT6wPEBvVQ>? MXXTRW5ITVJ?
SK-MM-2 M4r2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;T[3lEUUN3ME2xMlA6KG6P NFLGWpJUSU6JRWK=
VA-ES-BJ MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13kdGlEPTB;MT6wPUBvVQ>? Mn\hV2FPT0WU
MZ7-mel NITCcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:2[YxKSzVyPUGuNFkhdk1? M{XMN3NCVkeHUh?=
D-392MG NVXlOol1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvjWHJKSzVyPUGuNUBvVQ>? M1n1XHNCVkeHUh?=
CCRF-CEM MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3QTWM2OD1zLkGzJI5O M3PZ[XNCVkeHUh?=
EM-2 NFrjU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;QSGlEPTB;MT6xOkBvVQ>? MkH6V2FPT0WU
HAL-01 M2CwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\OdFN4UUN3ME2xMlE5KG6P Mn61V2FPT0WU
TE-8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HkRWlEPTB;MT6xPUBvVQ>? NFjaeHhUSU6JRWK=
NCI-H1882 M1u1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm1TWM2OD1zLkKgcm0> MnXlV2FPT0WU
Daudi NHjJcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fXc2lEPTB;MT6yNkBvVQ>? NGHTUFlUSU6JRWK=
BL-41 NX;wcYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrmTWM2OD1zLkK1JI5O MUnTRW5ITVJ?
SR Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TQTGlEPTB;MT6yOUBvVQ>? M4S1RnNCVkeHUh?=
KM12 NXHPeFl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X1fGlEPTB;MT6yO{BvVQ>? MUjTRW5ITVJ?
K5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH2S2pKSzVyPUGuNlghdk1? MmnxV2FPT0WU
A3-KAW MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TCN2lEPTB;MT6yPEBvVQ>? Ml73V2FPT0WU
CMK M2PMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TQPWlEPTB;MT6yPUBvVQ>? M3XQfXNCVkeHUh?=
Calu-6 M3jTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrNfZRKSzVyPUGuNlkhdk1? NUnsRWpFW0GQR1XS
IST-SL2 NVztVYtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjHTWM2OD1zLkOxJI5O MXrTRW5ITVJ?
OPM-2 NF;ibZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwM{Ogcm0> M1HuPHNCVkeHUh?=
DU-4475 NXW3c4gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrnbGRwUUN3ME2xMlM3KG6P NX7oXpIxW0GQR1XS
ECC12 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKwUZZKSzVyPUGuN|chdk1? MoLnV2FPT0WU
L-540 M33rRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImxVFZKSzVyPUGuN|chdk1? MVPTRW5ITVJ?
CAS-1 NYDGfHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LuOGlEPTB;MT6zO{BvVQ>? NVTQfXQxW0GQR1XS
PF-382 M3Tlfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS5e41KSzVyPUGuOFchdk1? M2PHZXNCVkeHUh?=
LS-411N MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2yeI93UUN3ME2xMlU{KG6P MVXTRW5ITVJ?
NCI-H69 NEftUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\vZmZDUUN3ME2xMlU1KG6P M2W3ZnNCVkeHUh?=
NB12 M4LmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPiTWM2OD1zLkW2JI5O NFz2V5RUSU6JRWK=
HEL Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H5OGlEPTB;MT62NUBvVQ>? MX;TRW5ITVJ?
GCIY MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLQVnM5UUN3ME2xMlYzKG6P NYLReXdZW0GQR1XS
EHEB NX;SUnVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknETWM2OD1zLk[3JI5O NXjxboZ5W0GQR1XS
TGBC1TKB MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz2fZNKSzVyPUGuO|Ehdk1? NV3LSol6W0GQR1XS
KURAMOCHI NHHCVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv4TWM2OD1zLkeyJI5O M1m3V3NCVkeHUh?=
U-266 NFuw[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwN{[gcm0> M2O3XnNCVkeHUh?=
LC4-1 M{\ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2yUpN1UUN3ME2xMlc6KG6P NXjZeotPW0GQR1XS
NCI-H2126 M4rrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqyTWM2OD1zLkigcm0> MVzTRW5ITVJ?
NCI-H1092 NHfkNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfn[oVKSzVyPUGuPEBvVQ>? NIW4WYVUSU6JRWK=
GB-1 NFTDV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PhOGlEPTB;MT64NUBvVQ>? M{jOOXNCVkeHUh?=
MV-4-11 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TITGlEPTB;MT64NkBvVQ>? M{\ZcXNCVkeHUh?=
Becker NHTZXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLoVFFlUUN3ME2xMlg{KG6P M{XMeXNCVkeHUh?=
MPP-89 NUDwNm01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwOEmgcm0> NI\WVFZUSU6JRWK=
BE-13 NY\GVHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPReIlKSzVyPUGuPVMhdk1? MlzrV2FPT0WU
697 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXFPWNOUUN3ME2xMlk6KG6P MWrTRW5ITVJ?
NKM-1 M1n4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxNGlEPTB;MjDuUS=> NIXRZmNUSU6JRWK=
NB13 NInFUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJibl2= NIDVOGtUSU6JRWK=
LS-123 M{SzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi1N3pKSzVyPUKuNFIhdk1? NUPwUItCW0GQR1XS
NB17 NHnvR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMESgcm0> M4\ucHNCVkeHUh?=
LAN-6 NGHsSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvtcnRGUUN3ME2yMlA2KG6P M2nYe3NCVkeHUh?=
EW-24 M4ja[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm3TWM2OD1{LkC4JI5O NV2wc5BOW0GQR1XS
NOS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXtWYdKSzVyPUKuNVEhdk1? NVjoU3oyW0GQR1XS
BL-70 NVzYNVU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fZU2lEPTB;Mj6xNkBvVQ>? M2LaXnNCVkeHUh?=
GT3TKB NH;iPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\jTWM2OD1{LkGyJI5O NXTEdW1VW0GQR1XS
HH MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC5Ro5YUUN3ME2yMlE{KG6P NHmzPWVUSU6JRWK=
KE-37 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW2TWM2OD1{LkGzJI5O Mmn6V2FPT0WU
MOLT-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn4S3FKSzVyPUKuNVMhdk1? NGq5SWJUSU6JRWK=
EKVX NHHPXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LZZ2lEPTB;Mj6xOEBvVQ>? MUXTRW5ITVJ?
KGN NU\zXVk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwMUWgcm0> NXy4[Ip4W0GQR1XS
ES4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnKTWM2OD1{LkG2JI5O Mlf5V2FPT0WU
SJSA-1 M1XjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwMkGgcm0> M1m0R3NCVkeHUh?=
KMOE-2 NXTZWYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjTN5J2UUN3ME2yMlI{KG6P MXzTRW5ITVJ?
NB5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LB[WlEPTB;Mj6yO{BvVQ>? MWDTRW5ITVJ?
BC-1 NV3FSoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv0PXZKSzVyPUKuN|Ehdk1? MUXTRW5ITVJ?
NB10 NX2ydY9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPVepZKSzVyPUKuN|Ihdk1? NXH4XlFvW0GQR1XS
RPMI-8226 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TxWWlEPTB;Mj6zOUBvVQ>? MUHTRW5ITVJ?
SCC-3 NV\WOlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[xdGlEPTB;Mj6zO{BvVQ>? M37DN3NCVkeHUh?=
ARH-77 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jvSGlEPTB;Mj6zPEBvVQ>? MUjTRW5ITVJ?
NCI-H748 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TQc2lEPTB;Mj6zPUBvVQ>? NHLhTmRUSU6JRWK=
KU812 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwNEKgcm0> NFrZN49USU6JRWK=
NCI-H64 NI\aflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqzTWM2OD1{LkS0JI5O M{LYUXNCVkeHUh?=
NB69 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrMSFJKSzVyPUKuOFYhdk1? NHPHbGlUSU6JRWK=
KNS-81-FD M2naR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULLcGJMUUN3ME2yMlQ5KG6P NFTxOmRUSU6JRWK=
LB1047-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHNcJRKSzVyPUKuOVchdk1? MoOwV2FPT0WU
EB-3 M4TUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwNk[gcm0> MormV2FPT0WU
Mo-T M3jMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33YcWlEPTB;Mj63OEBvVQ>? NEnTS2hUSU6JRWK=
EW-16 NWnQUIViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJwN{Wgcm0> NYiy[WI3W0GQR1XS
CTV-1 NF3Y[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPNUHdKSzVyPUKuPEBvVQ>? NW\TXIp2W0GQR1XS
ETK-1 NELqflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\1eJBFUUN3ME2yMlg1KG6P M{HPbHNCVkeHUh?=
C2BBe1 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy4U4JKSzVyPUKuPFkhdk1? NXzSNXNXW0GQR1XS
MOLT-16 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP0bnJKSzVyPUKuPFkhdk1? NI\rWmdUSU6JRWK=
SW954 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjQTWM2OD1{Lkmgcm0> M3jJWHNCVkeHUh?=
HT NFK2R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOxSIZKSzVyPUOuNFIhdk1? NYL2[pVKW0GQR1XS
KARPAS-299 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNwME[gcm0> M3\5bnNCVkeHUh?=
MONO-MAC-6 NWrsdYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrDPGcxUUN3ME2zMlEhdk1? NG[5VIFUSU6JRWK=
CGTH-W-1 M4ThUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTNwMTDuUS=> NFjQc3NUSU6JRWK=
SK-PN-DW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrhTWM2OD1|LkG0JI5O NUDuNlgyW0GQR1XS
CW-2 M1:wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[2UHJKSzVyPUOuNlEhdk1? NFLBbHZUSU6JRWK=
SK-N-DZ NFPaN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13WbWlEPTB;Mz6yOkBvVQ>? NVTSfZdwW0GQR1XS
NEC8 NELzNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNwM{Wgcm0> M1n2eXNCVkeHUh?=
LB996-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDQUodyUUN3ME2zMlQhdk1? MnjnV2FPT0WU
DB NYTCV2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLETWM2OD1|LkSxJI5O NHvjN3JUSU6JRWK=
TE-15 NFLJTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV64coNSUUN3ME2zMlQ{KG6P MV3TRW5ITVJ?
COR-L88 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrqZWRKSzVyPUOuOFchdk1? Ml3lV2FPT0WU
LAMA-84 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;zW2lEPTB;Mz60PUBvVQ>? NV\sPJV6W0GQR1XS
MEG-01 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknZTWM2OD1|LkS5JI5O MkDOV2FPT0WU
LOXIMVI M{LNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTNwNTDuUS=> M{iwb3NCVkeHUh?=
RPMI-8402 M4DNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T4PWlEPTB;Mz61JI5O MmrsV2FPT0WU
KARPAS-45 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTNwNUSgcm0> M3f2eXNCVkeHUh?=
HCC1187 M1X6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnHdGxKSzVyPUOuOVQhdk1? MmfOV2FPT0WU
MZ1-PC NFv6dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNwNUSgcm0> MnLEV2FPT0WU
no-11 NE\HdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHkfGFnUUN3ME2zMlU2KG6P M2PVfHNCVkeHUh?=
EVSA-T MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn4[plZUUN3ME2zMlYhdk1? MmO3V2FPT0WU
DJM-1 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwNkOgcm0> MY\TRW5ITVJ?
COLO-684 NWT5Sm55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjCUHZKSzVyPUOuOlYhdk1? MlHyV2FPT0WU
NMC-G1 NFfrWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwNkigcm0> NVm2U25DW0GQR1XS
LC-1F MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwN{Sgcm0> NWrzWIRLW0GQR1XS
RL95-2 M4i5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwN{mgcm0> NHzsWY9USU6JRWK=
COLO-320-HSR NUXRPFhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPwNnM4UUN3ME2zMlkzKG6P MX;TRW5ITVJ?
RCC10RGB MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPJTWM2OD1|LkmzJI5O NUHGSW1qW0GQR1XS
HD-MY-Z MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwOUOgcm0> M{nTe3NCVkeHUh?=
NCI-H2141 NVraZ5MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvxUIF2UUN3ME20MlA2KG6P Ml63V2FPT0WU
K-562 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRwMUKgcm0> M2e0WHNCVkeHUh?=
NCI-H1648 NGnpeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWyTWM2OD12LkGzJI5O MULTRW5ITVJ?
OMC-1 M4jCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTOeXd2UUN3ME20MlE5KG6P NXTxNJRoW0GQR1XS
LB647-SCLC NEDDTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rqZ2lEPTB;ND6yNkBvVQ>? MXPTRW5ITVJ?
TE-12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ObVFKSzVyPUSuNlUhdk1? M3LlbHNCVkeHUh?=
NOMO-1 NFHTV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv6TWM2OD12LkOzJI5O NWjkW4FPW0GQR1XS
Raji MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGxUplKSzVyPUSuOFYhdk1? NYrnU5N[W0GQR1XS
NALM-6 NWX6W2VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle4TWM2OD12LkS5JI5O M17t[HNCVkeHUh?=
HL-60 NVLmWJNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni3TWM2OD12Lk[3JI5O M2jpSHNCVkeHUh?=
IST-SL1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\5bGJKSzVyPUSuOlghdk1? MkPkV2FPT0WU
MHH-PREB-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTRwOE[gcm0> NVTmTohbW0GQR1XS
MHH-NB-11 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rSSGlEPTB;ND65NUBvVQ>? MkLKV2FPT0WU
JiyoyeP-2003 NWLUU5N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTlTWM2OD13IH7N M3u5[XNCVkeHUh?=
SBC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;RWJlKSzVyPUWuNFEhdk1? MnH1V2FPT0WU
CHP-126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLqVVlCUUN3ME21MlA3KG6P NYqzOIx7W0GQR1XS
LU-139 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\iNmNKSzVyPUWuNVMhdk1? MnvBV2FPT0WU
NCI-SNU-5 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XiT2lEPTB;NT6xO{BvVQ>? Mn;HV2FPT0WU
SW962 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrQ[YN6UUN3ME21MlIyKG6P Mlu4V2FPT0WU
EW-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M325fGlEPTB;NT6zNUBvVQ>? MYDTRW5ITVJ?
NCI-H1417 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPqPFNKSzVyPUWuOVEhdk1? NHTuNIVUSU6JRWK=
LU-65 NGHmO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn4NGlxUUN3ME21Mlg1KG6P M1zPb3NCVkeHUh?=
D-502MG NF3UbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPJNYFKSzVyPU[uN|chdk1? M3T1e3NCVkeHUh?=
BC-3 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\6TWM2OD14Lk[xJI5O MXPTRW5ITVJ?
GDM-1 NI\mbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZwN{egcm0> NH\QdFhUSU6JRWK=
NCI-H2196 NHXnPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTZwODDuUS=> NIHGVHpUSU6JRWK=
NB1 NE\2cXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHxTWM2OD14Lki4JI5O MoPXV2FPT0WU
NCI-H345 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXjXWREUUN3ME23MlIhdk1? MUDTRW5ITVJ?
SU-DHL-1 NVX0TmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjrOpJkUUN3ME23MlI1KG6P Ml3nV2FPT0WU
JVM-2 M{SwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S2cWlEPTB;Nz6yPEBvVQ>? M1O2W3NCVkeHUh?=
LU-134-A NWLo[|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLrTWM2OD15LkO5JI5O MojKV2FPT0WU
NCI-H1694 M17NO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTdwNUigcm0> Ml3lV2FPT0WU
NCI-SNU-16 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLYdGFKSzVyPUeuOlUhdk1? NWO5cm9[W0GQR1XS
L-363 NFrUOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTdwNzDuUS=> MnLqV2FPT0WU
KG-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXrbJRKSzVyPUeuPVQhdk1? NYDIelFwW0GQR1XS
MN-60 NYW0RpY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTXO2Z6UUN3ME24MlE1KG6P MYTTRW5ITVJ?
NB6 M2ezRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn70TWM2OD16LkS4JI5O NUfQWpJkW0GQR1XS
MLMA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO0T404UUN3ME24Mlg2KG6P M1f6OHNCVkeHUh?=
ATN-1 NYnofJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPBTWM2OD16Lki5JI5O M1HqdXNCVkeHUh?=
SK-NEP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\GZ3ZLUUN3ME25MlAyKG6P MYLTRW5ITVJ?
DMS-114 M{TSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\qUGlEPTB;OT62NkBvVQ>? NFu3bJFUSU6JRWK=
CTB-1 NYXxPItbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[3TWM2OD17Lk[3JI5O MnrSV2FPT0WU
NCI-H2081 M3vCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfBTWM2OD1zMD6wPUBvVQ>? NE\Td45USU6JRWK=
ES5 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPobGhKSzVyPUGwMlM5KG6P NXHXNXJFW0GQR1XS
HCC1599 NFvRZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7aTWM2OD1zMT65NUBvVQ>? M2nZcnNCVkeHUh?=
NCI-H23 NWXVR4N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13IRmlEPTB;MUKuNVIhdk1? NIXXTmhUSU6JRWK=
NCI-H1581 NYju[W1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG5cWJ6UUN3ME2xNk4zQCCwTR?= NEO2[mtUSU6JRWK=
JVM-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[zTZJ3UUN3ME2xNk46QSCwTR?= NF;lWlNUSU6JRWK=
NCI-SNU-1 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF|LkG5JI5O NIjoXmtUSU6JRWK=
NB7 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37vRmlEPTB;MUWuPVIhdk1? MnfJV2FPT0WU
JAR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF4LkGzJI5O M3u3WXNCVkeHUh?=
TGW NIXabFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrycWRvUUN3ME2xOk41QCCwTR?= MVzTRW5ITVJ?
U-87-MG Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXO[FBKSzVyPUG2Mlc3KG6P M4m1WXNCVkeHUh?=
NCI-H1436 M4PQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF5LkCxJI5O M1zSR3NCVkeHUh?=
GOTO NUOwO21zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P4OWlEPTB;MUeuNFYhdk1? NXP4Oow1W0GQR1XS
COLO-800 NUOwOoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiyco9uUUN3ME2xO{43PCCwTR?= NYHndnluW0GQR1XS
MFM-223 M4LHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DCcWlEPTB;MUeuPVEhdk1? NXr5UoZRW0GQR1XS
EW-18 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjtfYpKSzVyPUG3Mlk3KG6P MV;TRW5ITVJ?
NB14 NX\Lb2cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGji[JBKSzVyPUG3Mlk5KG6P NFzKN|BUSU6JRWK=
EB2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF6LkC4JI5O MXXTRW5ITVJ?
EoL-1- M3XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:5cWVKSzVyPUG4MlMyKG6P NXPTfVh4W0GQR1XS
NCCIT M3vBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSyTWM2OD1zOD6zOkBvVQ>? Mli0V2FPT0WU
DG-75 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF6Lk[xJI5O M{\VbnNCVkeHUh?=
HCC2218 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW3TWM2OD1zOT61JI5O NH24[HlUSU6JRWK=
TE-6 NUnMZVAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJyLkC4JI5O MofPV2FPT0WU
SF539 M1zkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJyLk[3JI5O Mki1V2FPT0WU
NCI-H446 M4X3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HOfGlEPTB;MkGuNVghdk1? NWf1NnlTW0GQR1XS
IST-MES1 NXnYZ5NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W2fWlEPTB;MkKuO|chdk1? NVzEWmVkW0GQR1XS
NCI-H82 M37hZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H5[mlEPTB;MkOuNFIhdk1? MnuyV2FPT0WU
HCC2157 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXrdGNUUUN3ME2yN{4yOyCwTR?= NUXV[|NOW0GQR1XS
EW-12 M1fXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojmTWM2OD1{Mz6xO{BvVQ>? M2PYVHNCVkeHUh?=
SIMA NXvXc2MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu3fohFUUN3ME2yN{4{QCCwTR?= MX3TRW5ITVJ?
DOHH-2 M{fiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ|LkS1JI5O MYjTRW5ITVJ?
IM-9 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXNNItwUUN3ME2yN{42PCCwTR?= M2r4PHNCVkeHUh?=
EC-GI-10 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ2LkKzJI5O MVLTRW5ITVJ?
HDLM-2 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H4e2lEPTB;MkSuOVQhdk1? NWTJVY1rW0GQR1XS
LS-1034 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr1fVlKSzVyPUK1Mlc2KG6P MYfTRW5ITVJ?
REH MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLKN2s{UUN3ME2yOk41OSCwTR?= M4qwW3NCVkeHUh?=
LU-165 NGPWNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJ4LkeyJI5O NFjoTpVUSU6JRWK=
NH-12 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K0TmlEPTB;MkeuOlchdk1? Mn3ZV2FPT0WU
WSU-NHL M4jnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M363WWlEPTB;MkiuN|khdk1? NGTBeoRUSU6JRWK=
ECC4 NYTu[HBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f2bGlEPTB;MkiuO|khdk1? NYDJe49TW0GQR1XS
OCI-AML2 NIn3XnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKzTWM2OD1{OT62PUBvVQ>? MXjTRW5ITVJ?
EW-3 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrVTWM2OD1|MD61PUBvVQ>? MWPTRW5ITVJ?
NCI-H526 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTN{LkW0JI5O NHjQSI1USU6JRWK=
NCI-H719 NUDBXHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknSTWM2OD1|ND6zNUBvVQ>? Ml\XV2FPT0WU
KARPAS-422 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\qTWM2OD1|NT6wOEBvVQ>? MX3TRW5ITVJ?
SK-MEL-1 NYHLXmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fKVmlEPTB;M{WuNVchdk1? MYDTRW5ITVJ?
ES3 NUO5[GpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN3LkG5JI5O MYrTRW5ITVJ?
UACC-812 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTQVmlVUUN3ME2zOU41PCCwTR?= NHHoV5RUSU6JRWK=
C8166 NYDFOYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[xZWlEPTB;M{WuO{BvVQ>? NHvzOnJUSU6JRWK=
MDA-MB-134-VI NX3NPIhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7qTWM2OD1|NT64O{BvVQ>? NG\ZSVJUSU6JRWK=
D-283MED NHewS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfIZ|E6UUN3ME2zO{44QSCwTR?= MX;TRW5ITVJ?
SHP-77 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnrTWM2OD1|OD6wN{BvVQ>? M3q1cXNCVkeHUh?=
NCI-H2227 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRyLkS5JI5O NInqUmxUSU6JRWK=
SKM-1 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD12Mj62N{BvVQ>? NWjyTplJW0GQR1XS
L-428 NEfSZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HxTmlEPTB;NEOuPFYhdk1? MUXTRW5ITVJ?
RPMI-6666 M{nrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXlcZRKSzVyPUS1Mlg6KG6P MnrOV2FPT0WU
NCI-H716 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37KemlEPTB;NEiuPFEhdk1? MV;TRW5ITVJ?
DMS-79 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXwTWM2OD13MD63NUBvVQ>? MWfTRW5ITVJ?
RS4-11 NYnKeVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTVyLki4JI5O NHfjUm9USU6JRWK=
NCI-H720 NVrSNotOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDJVZFKSzVyPUWxMlEyKG6P MnLsV2FPT0WU
MC-CAR NUjSfIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn6TXFKSzVyPUWxMlUzKG6P NHnUUIhUSU6JRWK=
TALL-1 M3n2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnISYNKSzVyPUWzMlkyKG6P MojUV2FPT0WU
NCI-N87 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPjXVZ2UUN3ME21OE4yQCCwTR?= MorOV2FPT0WU
P30-OHK M4\vPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PnOmlEPTB;NUSuOlEhdk1? MX3TRW5ITVJ?
LP-1 NH;hWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xj[mlEPTB;NkGuNlghdk1? MkC1V2FPT0WU
YT Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfURWVKSzVyPU[xMlghdk1? MYDTRW5ITVJ?
MRK-nu-1 M3fFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF65WG9KSzVyPU[xMlgzKG6P NWLpSW1RW0GQR1XS
BT-474 NVntNGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3NPIlUUUN3ME22OUBvVQ>? NEjqSHZUSU6JRWK=
NCI-H322M MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\RNGlEPTB;Nk[uNVEhdk1? MlPZV2FPT0WU
NCI-H128 M4O0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vKWGlEPTB;N{SuO|chdk1? MWXTRW5ITVJ?
KMS-12-PE NEflbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zuTWlEPTB;N{[uNlQhdk1? M2TMXHNCVkeHUh?=
KP-N-YS NUe0bIZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrjWpdKSzVyPUe2Mlc1KG6P NYDtclZRW0GQR1XS
ALL-PO NUfsWZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LrWGlEPTB;N{euOlYhdk1? MmKzV2FPT0WU
EW-13 NHzXRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX5TWM2OD15Nz63OkBvVQ>? MnTxV2FPT0WU
EW-11 M{i3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT5TWM2OD15OD61NkBvVQ>? MWfTRW5ITVJ?
SK-N-FI NGL2Zo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHwS25KSzVyPUiwMlIhdk1? MVjTRW5ITVJ?
CAL-148 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuwZ4w6UUN3ME24NU45PCCwTR?= M2n1bXNCVkeHUh?=
RL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTh4LkC5JI5O M{PwdnNCVkeHUh?=
AM-38 NF\KcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TOZ2lEPTB;OEiuNFghdk1? MUDTRW5ITVJ?
RH-1 M4fO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jsNmlEPTB;OUmuPFUhdk1? NXjqfHB7W0GQR1XS
NCI-H1770 M4Kwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImyc4RKSzVyPUGwNk41QSCwTR?= MkTiV2FPT0WU
SIG-M5 NHvSS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFyNT6wOkBvVQ>? MlzzV2FPT0WU
GR-ST MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLLUlNlUUN3ME2xNVMvOzRibl2= NHPMRWZUSU6JRWK=
ST486 NWrWOW44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;HWWlEPTB;MUG0MlA3KG6P MmPKV2FPT0WU
NCI-H1650 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;yVWlEPTB;MUG1MlI6KG6P M3HVTnNCVkeHUh?=
MHH-CALL-2 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvWeI5xUUN3ME2xNVUvPyCwTR?= MnzLV2FPT0WU
BV-173 NHu1Zo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ewS2lEPTB;MUKyMlcyKG6P NIPjXGFUSU6JRWK=
MC116 NFLjZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF2OD64OUBvVQ>? MYLTRW5ITVJ?
NCI-H524 NFiwV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO3UnBMUUN3ME2xOVkvOSCwTR?= MmexV2FPT0WU
SCLC-21H MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vWW2lEPTB;MUW5MlQyKG6P M1GxV3NCVkeHUh?=
NCI-H1304 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnwbWRLUUN3ME2xOlkvOjFibl2= M1:5cHNCVkeHUh?=
NCI-H510A NV7Fd|BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfHTWM2OD1zOEWuN|chdk1? MUnTRW5ITVJ?
NCI-H209 NUH0NYFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TJNmlEPTB;MUm2MlUzKG6P NUXqVVNUW0GQR1XS
KM-H2 Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL0ZVZ{UUN3ME2xPVcvODVibl2= NI\JflRUSU6JRWK=
NCI-H1395 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke4TWM2OD1{MUCuNVMhdk1? MVrTRW5ITVJ?
NCI-H1155 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6xXZdKSzVyPUKzNE4{OiCwTR?= NX\hfYk2W0GQR1XS
COR-L279 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fiV2lEPTB;MkWyMlE4KG6P M4PoWnNCVkeHUh?=
NCI-H1299 M1vnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ4MT63NUBvVQ>? Ml;iV2FPT0WU
EW-22 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP3TWM2OD1{NkOuO|Uhdk1? NXHs[49EW0GQR1XS
SK-MEL-2 M1rCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ6MT65JI5O NGHzcXVUSU6JRWK=
KASUMI-1 NX7SPJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTQTWM2OD1{OEOuNFUhdk1? M3nreHNCVkeHUh?=
NCI-H187 M{HDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ6Nz6wPEBvVQ>? MlW5V2FPT0WU
NCI-H2171 NGC4OFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT1epVyUUN3ME2yPFgvQTJibl2= NWDlU4NNW0GQR1XS
LNCaP-Clone-FGC NVjW[GtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzlTWM2OD1{OUWuNlYhdk1? M1LQWnNCVkeHUh?=
NCI-H1522 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTSTWM2OD1|MEeuNFUhdk1? MnfmV2FPT0WU
SCH NG\2NItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTN{Mj6yNkBvVQ>? MlqxV2FPT0WU
THP-1 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn0OoFbUUN3ME2zNlIvPiCwTR?= NGr5S4hUSU6JRWK=
SNU-C1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXUTWM2OD1|NkKuNFkhdk1? MmnRV2FPT0WU
CA46 NXGz[Y0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPDOZhxUUN3ME2zO|MvPjNibl2= NUXtNWJpW0GQR1XS
NCI-H1963 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fpdWlEPTB;M{i2MlE6KG6P NUjJbYFoW0GQR1XS
DEL NV:2VHhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTN7MT6yO{BvVQ>? NX3pNWRtW0GQR1XS
TUR Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN7Nj62NUBvVQ>? MVvTRW5ITVJ?
NCI-H226 M2\5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOzN|JKSzVyPUSwN{4zOyCwTR?= NWjXb4k5W0GQR1XS
COLO-668 NITw[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\qTWM2OD12MEOuOVchdk1? MYPTRW5ITVJ?
CPC-N M2Hsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX0cFh1UUN3ME20NFMvPzdibl2= NVHVWmZWW0GQR1XS
NCI-H889 NUTDUJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqzUI9{UUN3ME20OlEvQTJibl2= M4S5UnNCVkeHUh?=
J-RT3-T3-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfQfldsUUN3ME21N|IvPTdibl2= MXnTRW5ITVJ?
MSTO-211H MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfy[4FKSzVyPUW3OE4zPiCwTR?= MX3TRW5ITVJ?
SCC-15 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDTTWM2OD14NkeuOFchdk1? NVPHUZVJW0GQR1XS
SUP-T1 NX;rWYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHOTnBXUUN3ME22PFYvODRibl2= M{XCeXNCVkeHUh?=
DMS-153 NWjwN4tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTd2Nj64N{BvVQ>? MWTTRW5ITVJ?
MS-1 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXJbFNKSzVyPUe1PU41OiCwTR?= MXjTRW5ITVJ?
TC-YIK MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTd6MT6wNUBvVQ>? NWHuNoJ6W0GQR1XS
RPMI-8866 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZT5RKSzVyPUGwNFYvOjhizszN MVTTRW5ITVJ?
KY821 Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFyM{[uNFQh|ryP MkjzV2FPT0WU
P31-FUJ MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFzMUKuO|Uh|ryP MW\TRW5ITVJ?
COLO-824 NGjRUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF{NkGuO|gh|ryP MoLBV2FPT0WU
U-698-M NX:2NoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ{NkKuNVUh|ryP NFLEUJFUSU6JRWK=
TE-441-T NWjScZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT0UYpKSzVyPUK1NlEvPyEQvF2= MVXTRW5ITVJ?
IMR-5 M{n6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC3TWM2OD1|NEC5MlYzKM7:TR?= MmfzV2FPT0WU
NCI-H1838 NEnpbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\lTWM2OD12MUi2MlMzKM7:TR?= NIfFOGlUSU6JRWK=

... Click to View More Cell Line Experimental Data
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products3

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID